Michael Hearne - May 13, 2022 Form 4 Insider Report for LA JOLLA PHARMACEUTICAL CO (LJPC)

Signature
/s/ Michael Hearne
Stock symbol
LJPC
Transactions as of
May 13, 2022
Transactions value $
$641
Form type
4
Date filed
5/17/2022, 05:07 PM
Previous filing
May 3, 2022
Next filing
Jun 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LJPC Common Stock Award $641 +188 +2.01% $3.41 9.53K May 13, 2022 Direct F1
holding LJPC Common Stock 9.61M May 13, 2022 By LP F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LJPC Employee Stock Option (Right to Buy) Award $0 +188 $0.00 188 May 13, 2022 Common Stock 188 $4.01 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired on 5/13/2022 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2 The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Tang Capital Management, LLC ("TCM") is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as the Chief Financial Officer of TCM. Mr. Hearne has a pecuniary interest in the shares beneficially held by TCP.
F3 The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years.